BCHE and Alzheimer disease: For example, APOE4 carriers—especially those with concomitant BCHE-K alleles—are particularly responsive to AChE-I treatment in the mild stage of AD, and the magnitude of attention, processing speed, and amnestic deficits in these individuals may have been partly obscured [32].